Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CEO David M. Stack sold 28,885 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded down $0.72 during midday trading on Friday, reaching $41.50. 1,031,870 shares of the company’s stock were exchanged, compared to its average volume of 995,797. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1,680.00, a P/E ratio of -31.68 and a beta of 2.20.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. During the same period in the prior year, the company earned $0.20 EPS. Pacira Pharmaceuticals’s revenue was down 1.6% on a year-over-year basis. sell-side analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current year.
PCRX has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Bank of America decreased their target price on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 4th. Janney Montgomery Scott lowered shares of Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 target price for the company. in a research report on Thursday, October 26th. Royal Bank of Canada reiterated a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Friday, October 13th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $55.00 target price on shares of Pacira Pharmaceuticals in a research report on Friday, October 27th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $49.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/01/12/pacira-pharmaceuticals-inc-pcrx-ceo-david-m-stack-sells-28885-shares.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.